1. OP0090 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF CHRONIC LOW BACK PAIN: AN ANALYSIS OF BRIEF PAIN INVENTORY-SHORT FORM SCORES FROM A 56-WEEK, RANDOMIZED, PLACEBO- AND TRAMADOL-CONTROLLED, PHASE 3 TRIAL. (2nd June 2020) Authors: Markman, J.; Perrot, S.; Ohtori, S.; Schnitzer, T.; Beydoun, S.; Viktrup, L.; Yang, R.; Bramson, C.; West, C.; Verburg, K. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 1 (January 2018) Authors: van Schaik, Ivo N; Bril, Vera; van Geloven, Nan; Hartung, Hans-Peter; Lewis, Richard A; Sobue, Gen; Lawo, John-Philip; Praus, Michaela; Mielke, Orell; Durn, Billie L; Cornblath, David R; Merkies, Ingemar S J; Sabet, A.; George, K.; Roberts, L.; Carne, R.; Blum, S.; Henderson, R.; Van Damme, P.; D... Journal: Lancet neurology Issue: Volume 17:Issue 1(2018) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗